

Phospho S300 PDH E1 alpha protein (PDHA1) Profiling ELISA Kit ab115345

1 References 画像数 3

製品の概要

製品名	Phospho S300 PDH E1 alpha protein (PDHA1) Profiling ELISA Kit			
検出方法	Colorimetric			
再現性	Intra-Assay (同時再現性)			
	サンプル	N	平均値	SD
	1	8		CV%
				2.5%
	Inter-Assay (日差再現性)			
	サンプル	N	平均値	SD
	1	4		CV%
				7.8%
サンプルの種類	Cell culture extracts, Tissue Extracts			
アッセイタイプ	Sandwich (quantitative)			
検出感度	15 µg/ml			
検出範囲	15 µg/ml - 500 µg/ml			
ステップ	Multiple steps standard assay			
種交差性	交差種: Mouse, Rat, Cow, Human			
製品の概要	ab115345 is an in vitro enzyme-linked immunosorbent assay to determine the levels of phospho S300 PDHA1 protein in cell and tissue lysates. The assay employs a mouse antibody specific for PDHA1 protein coated on a 96-well plate. Samples are pipetted into the wells and PDHA1 protein present in the sample is bound to the wells by the immobilized antibody. The wells are washed and a rabbit anti-phospho S300 PDHA1 protein detector antibody is added. After washing away unbound detector antibody, HRP-conjugated anti-rabbit antibody is pipetted into the wells. The wells are again washed, an HRP substrate solution (TMB) is added to the wells and color develops in proportion to the amount of phospho S300 PDHA1 protein bound. The developing blue color is measured at 600 nm. Optionally the reaction can be stopped by adding hydrochloric acid which changes the color from blue to yellow and the intensity can be measured at 450 nm.			
特記事項	Store all components at 4°C. This kit is stable for 6 months from			

receipt. Unused microplate strips should be returned to the pouch containing the desiccant and resealed.

試験プラットフォーム

Microplate

製品の特性

保存方法

Store at +4°C. Please refer to protocols.

内容	1 x 96 tests
10X Blocking Buffer	1 x 6ml
10X HRP Label	1 x 1ml
10X phospho S300 PDHA1 protein Detector Antibody	1 x 0.7ml
20X Buffer	1 x 20ml
Extraction Buffer (ab260490)	1 x 15ml
Microplate 96 antibody coated wells in 12 strips	1 unit
HRP Development Solution	1 x 12ml

機能

The pyruvate dehydrogenase complex catalyzes the overall conversion of pyruvate to acetyl-CoA and CO₂. It contains multiple copies of three enzymatic components: pyruvate dehydrogenase (E1), dihydrolipoamide acetyltransferase (E2) and lipoamide dehydrogenase (E3).

組織特異性

Ubiquitous.

関連疾患


Defects in PDHA1 are a cause of pyruvate decarboxylase E1 component deficiency (PDHE1 deficiency) [MIM:312170]. PDHE1 deficiency is the most common enzyme defect in patients with primary lactic acidosis. It is associated with variable clinical phenotypes ranging from neonatal death to prolonged survival complicated by developmental delay, seizures, ataxia, apnea, and in some cases to an X-linked form of Leigh syndrome (X-LS).

Defects in PDHA1 are the cause of X-linked Leigh syndrome (X-LS) [MIM:308930]. X-LS is an early-onset progressive neurodegenerative disorder with a characteristic neuropathology consisting of focal, bilateral lesions in one or more areas of the central nervous system, including the brainstem, thalamus, basal ganglia, cerebellum, and spinal cord. The lesions are areas of demyelination, gliosis, necrosis, spongiosis, or capillary proliferation. Clinical symptoms depend on which areas of the central nervous system are involved. The most common underlying cause is a defect in oxidative phosphorylation. LS may be a feature of a deficiency of any of the mitochondrial respiratory chain complexes.


細胞内局在

Mitochondrion matrix.


画像



The PDHA1 bound from undosed HeLa cells was subject to in-well kinase treatment (PDK1&3) or in-well phosphatase treatment(PDP1) according to the supplementary protocol shown below. Untreated cells did not show a significant endogenous phosphorylation signal at S300 this could be increased by kinase treatment. Phosphatase treatment had no effect on the endogenous (low) level of phospho S300 signal.



HeLa cells were cultured for 4 hours in media supplemented with DCA (20mM) to specifically inhibit mitochondrial PDH kinases, or NaF (20mM), a general inhibitor of serine/threonine protein phosphatases. The DCA treatment did not reduce the level of phospho S300 confirming that there is little endogenous phospho S300. Conversely NaF treatment, to inhibit cellular serine phosphatases, did increase the phosphorylation level of S300.



The phosphorylation state of PDHA1 can vary by treatment but also by cell culture conditions such as media supplements, nutrients and also cell density.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"

Our Abpromise to you: Quality guaranteed and expert technical support

- Replacement or refund for products not performing as stated on the datasheet
- Valid for 12 months from date of delivery
- Response to your inquiry within 24 hours
- We provide support in Chinese, English, French, German, Japanese and Spanish
- Extensive multi-media technical resources to help you
- We investigate all quality concerns to ensure our products perform to the highest standards

If the product does not perform as described on this datasheet, we will offer a refund or replacement. For full details of the Abpromise, please visit <https://www.abcam.co.jp/abpromise> or contact our technical team.

Terms and conditions

- Guarantee only valid for products bought direct from Abcam or one of our authorized distributors